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AnticoagulationBackground:Althoughmedicalmanagement of patients with coronary artery disease (CAD) is often based on sci-
entiﬁc guidelines, a number of everyday clinical situations are not speciﬁcally covered by recommendations or
the level of evidence is low. The aim of this study was to assess practice patterns regarding routine management
of patients with stable CAD.
Methods:A survey comprising six questions on two clinical scenarios regarding stable CADmanagementwas sent
to 345 cardiologists from the Nord-Pas-de-Calais Region (France). We ﬁrst assessed practice patterns globally
and then searched for associations with physician characteristics (age, gender, sub-specialty, and type of prac-
tice).
Findings: The response rate was 92%. Regardingmanagement of asymptomatic CAD, 86% of the cardiologists per-
formed routine exercise testing, beforewhich, 69%withdrewβ-blockers. After a positive exercise test, 26% imme-
diately performed coronary angiography and 67%, further imaging tests. In the absence of left ventricular
dysfunction or history of myocardial infarction, routine β-blocker prescription for stable CAD was selected by
43%. When anticoagulation was needed for atrial ﬁbrillation, 41% initiated direct oral anticoagulants rather
than vitamin-K antagonists and 50% combined aspirin with anticoagulants. For recurrent stable angina in pa-
tients with known CAD, 24% performed coronary angiography directly, 49% requested a stress test, and 27%
opted for medical therapy without further diagnostic testing. Age, gender of the cardiologist, academic environ-
ment, and practice of interventional cardiology were associated with certain management patterns.
Interpretation:When not guided by high-level recommendations, practice patterns for routine clinical situations
in stable CAD vary considerably. Future clinical trials should address these clinical interrogations.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD) is a leading cause of mortality and
morbidity worldwide (Roth et al., 2015). The medical management of
CAD patients is increasingly dictated by clinical practice guidelines is-
sued by experts and scientiﬁc authorities (Fihn et al., 2012;
Montalescot et al., 2013; Steg et al., 2012; O'Gara et al., 2013;
Windecker et al., 2014). However, certain clinical decisions, including
routine decisions, are not speciﬁcally covered by guidelines or the
level of evidence is low (Tricoci et al., 2009). Examples of these everydayRU de Lille, Boul. Prof. Leclercq,
uters).
. This is an open access article underclinical situations are: routine exercise testing in asymptomatic patients
with known CAD, the management of asymptomatic CAD patients with
positive exercise tests, the management of CAD patients with recurrent
chest pain, or the management of such patients with atrial ﬁbrillation
requiring anticoagulation. In these cases, the medical choice may de-
pend primarily on the physician's opinion, personal experience and
preferences. There is currently a paucity of literature addressing these
issues, and little is known about the variability in practice among cardi-
ologists.We therefore designed the present study to: (1) assess practice
patterns regarding the routine management of patients with stable
CAD; and (2) analyze whether several variables (age and gender of
the cardiologist, type of cardiology practice, etc.) are associated with
speciﬁc medical decisions. To this end, the cardiologists of a geographi-
cal region of France, where the prevalence of cardiovascular disease is
high (Tunstall-Pedoe et al., 1994), were all invited to take part in a
case vignette-based survey (Tunstall-Pedoe et al., 1994).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Survey Design
We conducted a cross-sectional survey of cardiologists in the Nord-
Pas-de-Calais Region (population, 4.05 million) of France. A mailing list
of cardiologists actively working in the area was built up from the list of
physicians certiﬁed in cardiology (N=414) and cross-checkedwith pro-
fessional directories. Physicians working solely as pediatric cardiologists
and those working solely as vascular physicians were not included in
the survey. Physicians with a cardiology certiﬁcation but for whom clini-
cal cardiology was not the primary activity were also excluded, as were
those who had recently retired. We ended up with a list of 345 cardiolo-
gistswhowere the target population of the present study. The surveywas
sent out in December 2014 using the French Postal Service. A reminder
notice was sent in February 2015. The project was approved by the local
Institutional Review Board of the University Hospital of Lille (France).
2.2. Questionnaire
The survey tool was developed by cardiologists routinely involved in
the clinical care of CAD patients. To maximize the response rate, we de-
veloped a very simple, anonymous questionnaire that could beTable 1
Case #1.
A 62-year-old man has sustained an inferior ST segment-elevation MI. He has
undergone successful primary angioplasty with implantation of a drug-eluting
stent for acute occlusion of the right coronary artery. There were no other
signiﬁcant coronary lesions, and the left ventricular ejection fraction at hospital
discharge was 55%. Smoking was the sole cardiovascular risk factor and was
stopped at time of MI. Six months after MI, an exercise test was performed (80%
of maximum predicted heart rate; negative).
At present, two years post-MI, the patient is asymptomatic and is receiving
optimal medical therapy for secondary prevention.
Assuming that the patient is still asymptomatic:
1. During this latest visit (2 years after MI), you send him for a non-invasive stress
test to screen for myocardial ischemia
2. You wait 3 years after MI before sending him for a stress test
3. You wait 4 years after MI before sending him for a stress test
4. You wait 5 years after MI before sending him for a stress test
5. You do not send the patient for a stress test as long as he remains
asymptomatic
Choose only one answer (your ideal choice)
Assuming that you send the patient for a treadmill exercise test and that he has
been on β-blockers since his MI:
1. You tell him to stop taking the β-blocker before the test
2. You maintain treatment with the β-blocker for the test
Choose only one answer (your ideal choice)
Assuming that you send the patient for a treadmill exercise test and that the
results are as follows: exercise duration on BRUCE protocol: 11 min; test stopped
for fatigue at 90% of maximum predicted heart rate; no chest pain; no
arrhythmia; signiﬁcant downsloping ST-segment depression at 9 min (reaching
1.4 mm at peak exercise).
1. You send the patient for a coronary angiography
2. You do not send the patient for additional tests. You simply plan clinical
follow-up (unless the patient becomes symptomatic)
3. You do not send the patient for additional tests. You increase the anti-ischemic
medication and organize clinical follow-up (unless the patient becomes
symptomatic)
4. You send the patient for a second non-invasive test (stress echocardiography,
nuclear stress test). If ischemia is conﬁrmed, you send the patient for a coro-
nary angiography. If the second test is negative, you organize clinical follow-up
(unless the patient becomes symptomatic)
Choose only one answer (your ideal choice)
MI, myocardial infarction.answered quickly. The survey consisted of six questions pertaining to
two clinical scenarios regarding stable CAD patients (Tables 1 and 2).
Demographic information (age and gender of the cardiologist, private
vs. hospital practice, academic vs. non-academic cardiologist, interven-
tional [coronary] vs. non-interventional cardiologist) was recorded to
further deﬁne the participating population of physicians.2.3. Statistical Analysis
Statistical analyses were performed with the SPSS 20.0.0 IBM soft-
ware. Continuous variables are presented as means ± standard devia-
tion (SD). Categorical variables are presented as absolute numbers
and/or percentages. Univariate analysis using the χ2 test was performed
to search for associations between answers and physician characteris-
tics (age tertiles, gender, private vs. hospital practice, academic vs.
non-academic, interventional vs. non-interventional cardiologist). Lo-
gistic regression analysis was used to determine which physician char-
acteristics were independently correlated with management patterns.
Odds ratios (OR) and corresponding 95% conﬁdence intervals (CI)
were calculated. Statistical signiﬁcance was assumed at P-value b 0.05.Table 2
Case #2.
A 76-year-old diabetic woman underwent coronary angiography because of
exercise-induced angina (no history of MI). Three-vessel coronary disease was
documented. Firstly, a right coronary stenosis, which appeared as the more
severe lesion, was treated by implantation of a drug-eluting stent. However, the
patient remained symptomatic, and a CABG (left anterior descending artery, left
marginal artery) was performed.
After surgery, the patient joined a cardiac rehabilitation program. At the end of
the program, the exercise test was submaximal but showed no sign of ischemia.
Left ventricular ejection fraction was 60%.
Three months after CABG, the patient is doing well. She has no angina. Blood
pressure is 130/80 mm Hg, and heart rate is 67 beats/min (in sinus rhythm).
Medical treatment includes low-dose aspirin, a statin, an ACE inhibitor, and
treatment for diabetes. LDL-cholesterol and glycosylated hemoglobin are well
controlled. Renal function is normal.
Would you add a β-blocker?
1. Yes
2. No
Choose only one answer (your ideal choice)
Two years later, atrial ﬁbrillation is diagnosed. The patient still has no symptoms of
angina. Which anticoagulation treatment would you choose?
1. Vitamin-K antagonist and discontinue aspirin
2. Vitamin-K antagonist and continue with aspirin
3. Direct oral anticoagulant and discontinue aspirin
4. Direct oral anticoagulant and continue with aspirin
Choose only one answer (your ideal choice)
The patient is now 84 years old (CABG was performed 8 years ago). She has
osteoarthritis and is no longer very active. During a routine outpatient visit, the
patient reported recurrent angina that began approximately 6 months
previously. The chest pain is similar to what she experienced prior to CABG,
although less severe (only 1 or 2 episodes per month, when she goes shopping,
and with rapid [≤1 min] spontaneous cessation at rest).
1. You send the patient for a coronary angiography
2. You send the patient for a non-invasive stress test. If positive, you send her for a
coronary angiography
3. You send the patient for a non-invasive stress test. If positive, you increase
anti-ischemic medication and continue with clinical follow-up
4. You do not send the patient for additional tests. You simply increase anti-
ischemic medication and pursue clinical follow-up
Choose only one answer (your ideal choice)
MI, myocardial infarction. CABG, coronary artery bypass graft. ACE, angiotensin-
converting enzyme.
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The response rate to the surveywas very high (318 out of 345; 92%).
Mean age of the participating cardiologists was 49.2 ± 11.4 years
(range, 27 to 73 years); 250 (79%) were men. One hundred seventy
three (54%) cardiologists were working in private practice and the
others (145; 46%) in public hospitals; 34 (11%) were academic physi-
cians. Seventy nine (25%) of the responding physicians were (at least
part-time) interventional cardiologists.
Case #1 (Table 1) focuses on a 62-year-oldmanwho is asymptomat-
ic two years after a myocardial infarction (MI) for which he underwent
primary percutaneous coronary intervention (PCI) with complete re-
vascularization. The answers to the questions are shown in Fig. 1a. The
majority of cardiologists (86%) stated that theywould perform a routine
stress test in this situation, even if the patient was asymptomatic, and in
most instances, at the time of this visit (two years after MI). Of note, 43
cardiologists (14%) answered that theywould not prescribe a stress test
as long as the patient remains asymptomatic. Most physicians (69%)
would advise patients on β-blockers to discontinue the drug prior to ex-
ercise testing. The last question pertains to patient management if the
exercise test suggests silent ischemia with preserved exercise capacity.
In this instance, the vast majority of cardiologists would ask for addi-
tional tests (either coronary angiography directly [26%], or further im-
aging tests, followed by coronary angiography if ischemia is conﬁrmed
[67%]); the proportion of physicians who would simply continue with
clinical follow-up (with or without increasing anti-ischemic medica-
tion) was low (7%).
Case #2 (Table 2) focuses on a 76-year-oldwomanwith 3-vessel dis-
easewhohas undergone coronary artery bypass graft (CABG) combined
with drug-eluting stent (DES) implantation. She is currently asymptom-
atic, has no history of MI, and has normal left ventricular ejection
fraction. The answers to the questions are shown in Fig. 1b. Forty
three percent of the cardiologists stated that they would prescribe a
β-blocker for secondary prevention in such a patient. In the event of
atrial ﬁbrillation two years later requiring chronic oral anticoagulation,
59% would use a vitamin-K antagonist (VKA) and 41%, a direct oral an-
ticoagulant (DOA); in both groups, half the cardiologistswould combine
low-dose aspirin with anticoagulation, while the other half would use
anticoagulation alone. The last question concerns patient management
should recurrent, non-severe stable angina occur eight years after
revascularization, at a time when the patient is no longer physicallyFig. 1. Responses to the survey. Panel a: Responses to questions of case #1. Panel b: Responses to
CAD, coronary artery disease; VKA, vitamin-K antagonist, DOA, direct oral anticoagulant; ASA,very active. In this situation, most physicians would ask for additional
tests (coronary angiography [24%], or a non-invasive stress test follow-
ed by coronary angiography if ischemia is conﬁrmed [49%]) but a sub-
stantial proportion (27%) would ﬁrst opt to increase anti-ischemic
medication.
We then investigated whether physician characteristics (age, gen-
der, academic vs. non-academic, private vs. hospital practice, interven-
tional vs. non interventional cardiologist) were associated with
answers to the questions (Fig. 2). Although globally, practice patterns
appeared relatively similar among subgroups, therewere several differ-
ences that reached statistical signiﬁcance. After adjustment for all phy-
sician characteristics, older physicians were more likely to discontinue
β-blockers before performing exercise testing (OR = 2.38 [1.21–4.68]
for physicians ≥55 years of age vs. b45 years), more likely to prescribe
a combination of aspirin and anticoagulants (OR = 2.40 [1.35–4.26]
for physicians ≥55 years of age vs. b45 years) and to request coronary
angiography directly in the event of recurrent angina (OR = 2.23
[1.17–4.24]). Male cardiologists were less likely to prescribe
β-blockers for stable CAD (OR = 0.51 [0.30–0.87]), and more likely to
prescribe DOAs if an anticoagulant was indicated (OR = 2.76 [1.47–
5.17]). Interestingly, cardiologists working in an academic environment
were less likely to prescribe routine exercise tests in asymptomatic
stable CAD patients (OR = 0.22 [0.10–0.50]), less likely to discontinue
β-blockers before exercise testing (OR = 0.24 [0.11–0.53]), less likely
to combine aspirin with anticoagulants (OR = 0.37 [0.16–0.86]), and
had a greater tendency to initiate treatment with DOAs (OR = 2.19
[0.97–4.92]). Lastly, the type of practice (private fee-for-service vs.
employment by public institutions) had little inﬂuence on management
patterns, while interventional cardiologists were less likely to discontin-
ue treatment with β-blockers before performing exercise testing (OR=
0.48 [0.27–0.84]) and more likely to prescribe immediate coronary
angiography in the event of recurrent angina (OR = 2.33 [1.31–4.14]).
4. Discussion
Nowadays, the expected long-term survival of the vast majority of
patientswith CAD is excellent, with few recurrent cardiovascular events
(Bauters et al., 2014a). During this prolonged period of outpatient care,
diagnostic and therapeutic decisions by the referring cardiologist are
major drivers of patient management. As highlighted above, recom-
mendations based on high levels of evidence are often lacking forquestions of case #2. The 2 clinical scenarios are presented in Tables 1 and 2, respectively.
aspirin and AF, atrial ﬁbrillation.
1665C. Bauters et al. / EBioMedicine 2 (2015) 1662–1668
Fig. 2. Associations between physician characteristics and survey responses.Panel a: age. Panel b: gender. Panel c: academic vs. non-academic practice. Panel d: private vs. hospital practice.
Panel e: interventional vs. non interventional cardiologist. The P value on the bar graph is for univariate analysis. The odds ratio (OR) below the graph is adjusted for other physician char-
acteristics. The 2 clinical scenarios are presented in Tables 1 and 2, respectively.CI, conﬁdence interval and CAD, coronary artery disease.
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tionally restricted in scope to ensure quick answers from participating
physicians, the present survey nevertheless addresses several diagnos-
tic and therapeutic issues that are extremely common for most cardiol-
ogists in everyday practice and forwhich the level of evidence is limited.
Case #1 concerns the use of non-invasive stress tests in an asymp-
tomatic post-MI patient. It is not currently known whether routine
tests in this situation are beneﬁcial, as no trial has assessed the impact
of routine exercise testing on the clinical outcome of stable CAD pa-
tients. According to the European Guidelines (Montalescot et al.,
2013), repetition of an exercise ECG in stable CAD patients may only
be considered at least two years after the previous test (a class IIb
level C-recommendation). According to the American Appropriate Use
Criteria (Wolk et al., 2014), non-invasive stress tests in asymptomatic
patients with known CAD are rated ‘rarely appropriate’ if performed
b5 years after CABG or b2 years after PCI, and ‘may be appropriate’
≥5 years after CABG or ≥2 years after PCI. Our results show that, despite
these ‘neutral’ recommendations, the use of routine stress tests is a
very ﬁrmly established practice among cardiologists. It is howevernoteworthy that variability exists with regard to this observation, and
that about 15% of the physicians considered that routine stress testing
is not useful as long as the patient remains asymptomatic. Beta adrener-
gic blocking agents can reduce or delay the onset of angina pectoris
and ST segment depression on exercise testing (Ho et al., 1985).
We observed that about 2/3 of cardiologists would advise patients on
β-blockers to discontinue this treatment prior to exercise testing.
There are no clear guidelines on this question, and there would appear
to be two different standpoints: (i) β-blockers should be stopped
because this approach will maximize the ability of the test to detect
ischemia; (ii) β-blockers can be maintained since there is no point in
‘detecting’ medically controlled ischemia in patients with documented
CAD. Importantly, the approach based on practice of routine non-
invasive stress tests cannot be separated from its consequences when
the results are known. Although a normal test in this context is simple
to manage andwill be seen as reassuring by both patient and physician,
it is important to determine the extent to which a test suggestive of
ischemia is likely to impact on patient management. We intentionally
chose a scenario in which exercise testing suggests ischemia without
1667C. Bauters et al. / EBioMedicine 2 (2015) 1662–1668any markers of high-risk (preserved exercise capacity, moderate ST
deviation, no angina during exercise), i.e., a situation where revascular-
ization is unlikely to lead to improved event-free survival (Boden et al.,
2007). In spite of this, our results show that a positive exercise test will
almost inevitably lead to coronary angiography being performed, if
ischemia is not ruled out by additional tests.
Case #2 addresses a sequential approach to three different therapeu-
tic and diagnostic decisions pertaining to the stable CAD patient. (i) Al-
though there is no discussion about the fact that patients with systolic
heart failure should receive a β-blocker (McMurray et al., 2012; Yancy
et al., 2013), there is no evidence from randomized evaluations that β-
blockers improve survival in the rest of the stable CAD population (ex-
cluding the early post-myocardial infarction period), and observational
studieswith propensity score adjustments have provided discordant re-
sults (Bangalore et al., 2012; Bauters et al., 2014b). Our data, showing
that approximately 50% of the participating cardiologists would opt
for aβ-blocker in such patients, are thus concordantwith the current lit-
erature. (ii)When atrial ﬁbrillation develops in an otherwise stable CAD
patient, it can prove difﬁcult to ﬁnd the best antithrombotic regimen
with the most favorable risk-beneﬁt ratio. International guidelines on
atrial ﬁbrillation have suggested that, in patients with stable vascular
disease (i.e., N1 year with no acute events), oral anticoagulation mono-
therapy may be considered (Camm et al., 2010; Fuster et al., 2011). It
was however acknowledged that the level of evidence was low (class
IIb level C-recommendation for both European and American guide-
lines) (Camm et al., 2010; Fuster et al., 2011), and data from recent reg-
istries have shown that in the realworld, physicians are still reluctant to
discontinue all antiplatelet therapy in CAD patients who need oral
anticoagulation (Hamon et al., 2014; Lamberts et al., 2014). Again, the
results of our survey show a balanced ﬁgure with 50% of cardiologists
whowould continue aspirin and 50%whowouldwithdraw it (irrespec-
tive of the choice of anticoagulant). The fact that our ﬁctitious patient
had undergone DES implantation, even though it was over two years
beforehand, may have affected the decision to pursue with aspirin.
(iii) The last question relates to the management of recurrent angina
in an elderly patient with a past history of PCI and CABG. Although a
quarter of the cardiologists replied that pharmacological treatment
would be their ﬁrst-line choice, most physicians appeared to have a
more invasive approach, and would recommend coronary angiography
(either immediately, or once ischemia has been conﬁrmed by a non-in-
vasive test).
Our secondobjectivewas to analyzewhether certain physician char-
acteristicsmay play a role in these diagnostic and therapeutic decisions.
In contrast to what might have been expected, younger cardiologists
were not more aggressive than older ones. In fact, if anything, the re-
verse trend was observed, with older cardiologists more likely to stop
β-blockers before performing exercise testing, more likely to combine
antiplatelet and anticoagulant agents, and more likely to prescribe cor-
onary angiography directly in the cases of recurrent angina in elderly
patients with known CAD. One possible explanation for this latter ﬁnd-
ingmight be the fact that this strategywasmore prevalent in the past, at
a time when non-invasive tests were not so widely used, but possibly
also when it was believed (before the results of randomized clinical tri-
als; Boden et al., 2007) thatmyocardial revascularizationmight improve
survival in stable patients. Female physicians appeared more reluctant
to use DOAs, and more prone to prescribe β-blockers as a routine pre-
ventive medication in asymptomatic patients after CABG; this might
be interpreted overall as a more cautious attitude. In contrast, academic
cardiologists were more likely to adopt new drug approaches, such as
DOAs, or newer attitudes such as prescribing anticoagulants alone rath-
er than dual antithrombotic therapy when anticoagulants were needed.
The results of trials comparing DOAs and vitamin K antagonists are rel-
atively recent, as are the guidelines (2010–2011) suggesting that oral
anticoagulation alone may be a safe option in stable CAD (Camm et al.,
2010; Fuster et al., 2011), and these conclusions may well have been
more readily adopted by the academic community. One could havehypothesized that cardiologists in private practice may have speciﬁc
practice patterns, related to the personal ﬁnancial impact of test pre-
scription. This was however not so clear-cut; in virtually all respects,
private cardiologists gave similar answers to those of cardiologists
working in hospitals. Similarly, one might have expected to observe a
more aggressive approach (tendency toward using more tests and cor-
onary angiographies) by interventional cardiologists. Again there was
no indication for this, with the one possible exception of their more
frequent decision to go directly to coronary angiography in the
cases of recurrent angina in patients with known CAD; on the other
hand, interventional cardiologists were less likely to discontinue β-
blockers before prescribing an exercise test. Overall, the type of med-
ical practice had relatively little inﬂuence on management patterns.
Other than the fact that continuous medical education programs
for both private and public sector cardiologists are similar, this
could be partly explained by the new system of funding of public
hospitals in France (“tariﬁcation à l'activité”), which has been in
place since 2007 and actually encourages physicians to use tests or
procedures (typically, coronary angiography) that are highly valued
in terms of state funding to their institutions. In other words, the cur-
rent health system in France encourages physicians to use tests/pro-
cedures rather than simply provide clinical care to their patients:
private cardiologists earn more if they perform such tests, while
the institutions employing public-sector cardiologists beneﬁt directly
from the use of these tests.4.1. Strengths and Limitations
The main strength of our survey is the very high response rate
(N90%) among a population comprising all the practicing cardiologists
in a speciﬁc region of France known to have a high prevalence of CAD
(Tunstall-Pedoe et al., 1994), together with a large sample size (N300
cardiologists). A response rate such as this is unusually high for this
type of survey, and the results can therefore be considered as represen-
tative of the physicians' opinions. Conversely, themain limitation is that
the results only reﬂect the medical practice in one geographical region
comprising approximately 4 million inhabitants, and therefore may
not be adequately representative of the rest of the country, or indeed
other countries. In particular, regional academic leadership may affect
medical practice differently from one region to another. In the Nord-
Pas-de-Calais Region, the regional academic leadership is based on an
annual 2-day regional meeting, and on smaller thematic workshops.
In addition, biannual 2-day regional seminars are part of the cardiology
fellowship program. Because of the increasing development of national
or European continuous medical education programs, and the constant
ﬂow of information from internet-basedmedical sites, regional speciﬁc-
ities are however less likely to exist than in the past. The degree ofﬁnan-
cial support–reimbursement regardingmedical care is also likely to be a
determinant of practice patterns. In France, social coverage and health
insurance are uniform over the whole territory, and chronic CAD is
one of the long-term conditions entitled to full reimbursement of all
costs, including diagnostic procedures and medications. Comparing
practice patterns in different countries with other medical care systems
would be of interest. Finally, answers to case-vignettes may differ from
actual practice when physicians are confronted with similar real-life
clinical cases. Although comparison with real-world practice is difﬁcult
because of the paucity of data available, it is noteworthy that the 24%
rate of physicians going directly to coronary angiography in CAD pa-
tients with recurrent stable angina is perfectly in line with the results
of the large French registry on coronary angiography and PCI. This ob-
servational study conducted by the French Society of Cardiology
assessed treatment strategies in a population of 298,105 patients and
showed that 25% of those with stable symptoms had undergone direct
angiography without prior exercise or imaging stress testing
(Puymirat et al., 2013).
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Diagnostic and therapeutic practice for extremely common, every-
day clinical situations vary considerably among physicians when man-
agement attitudes are not guided by clear recommendations.
Although several drivers of management behavior can be identiﬁed
from the cardiologists' proﬁles, theﬁnal clinical decision remains largely
unexplained. Overall, cardiologists in our survey were seen to be more
likely to have ‘protective’ attitudes and use diagnostic tests or therapies
despite the absence of a rational scientiﬁc basis, than to adopt more
‘conservative’ attitudes. Beyond the uncertain consequences of such at-
titudeswith regards to patient health, they are likely to have a consider-
able economic cost for the society. There is therefore an urgent need for
novel clinical trials to address these interrogations and to “close” gaps in
current recommendations.
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